Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Curis reports net loss of $2.1 million for second-quarter 2010

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended June 30, 2010.

3 Aug 2010

New trend in management of post-liver transplantation biliary strictures

Endoscopic intervention has emerged to become the first line treatment for benign biliary strictures following liver transplantation. The current endoscopic approach involves repetitive dilatation of the stricture and placement of multiple large-diameter parallel plastic stents with frequent stent exchange to prevent biliary infection.

3 Aug 2010

NYU PRC receives $3.2M award to establish Comparative Effectiveness Research Program

The NYU Health Promotion and Prevention Research Center at the NYU School of Medicine announced it has received a $3.2 million award from the Centers for Disease Control and Prevention to establish a Comparative Effectiveness Research Program focused on hypertension and colorectal cancer health disparities in African-American men in New York City.

2 Aug 2010

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Vanishing bile duct syndrome refers to a group of disorders characterized by destruction and disappearance of intrahepatic (inside the liver) bile ducts. Multiple causes have been identified including infections, malignancies, autoimmune conditions and adverse effects of medications. The usual course of this condition is variable and many patients with VBDS respond to treatment of the underlying condition and/ or removal of the offending agent. However, others progress to cirrhosis and end stage liver disease requiring liver transplantation.

31 Jul 2010

Exposure of mBM-MSCs to VPA increases hepatic differentiation

Recent studies suggest that MSCs possess a greater differentiation potential than once thought and several hepatic differentiation protocols from bone marrow cells have been established. However, the incidence of bone marrow-derived hepatocytes was low. Moreover, a long culture period is needed in most cases.

31 Jul 2010

Patients with malignant gastrointestinal disease show high prevalence of malnutrition

Malnutrition is an important factor, influencing both morbidity and recovery after surgery. The early detection of nutritional risk would allow early intervention, which may prevent later complications. A traditional nutritional assessment often includes dietary and medical evaluations to identify significant weight loss over time, significantly low or high body weight(BW), skinfold thickness, serum nutritional factor levels and functional measurements of muscle strength.

31 Jul 2010

Galangin mediates apoptosis of hepatocellular carcinoma cells through mitochondrial pathway: Study

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, particularly in China. However, HCC remains one of the more difficult cancers to treat. It is important to screen for new anti-cancer drugs. A number of dietary compounds possess anti-cancer properties. These dietary compounds may modify the activity of specific targets that control cell proliferation and apoptosis. Galangin could inhibit the methoxyresorufin O-demethylase activity of CYP1A2, CYP1A1 and P-form phenolsulfotransferase.

31 Jul 2010

CD74 can serve as prognostic marker for colorectal cancer

CD74 is a protein that is expressed in and on cells of the immune system, such as B lymphocytes and antigen presenting cells. This protein is known for its function in facilitating antigen presentation enabling the immune response. Additionally, Professor Shachar's lab has previously shown that CD74 serves as a survival receptor on cells of the immune system, and that its stimulation by its natural ligand -migration inhibitory factor (MIF)- prevents apoptosis (self destruction) of these cells. It was shown that CD74 is markedly expressed on numerous tumors - hematologic as well as epithelial, and can serve as a prognostic marker. CD74's expression and function on colon intestinal epithelial cells is controversial.

31 Jul 2010

Functional MRI can be used to assess tumor viability

Pancreatic ductal adenocarcinoma (the disease commonly referred to as pancreatic cancer) carries the worst prognosis of any cancer. As current treatments offer minimal benefit, entirely new approaches are needed. Given the success of local therapies, as opposed to intravenous systemic therapies, for liver diseases (such as hepatocellular carcinoma), it is thought that similar local therapies may benefit patients with pancreatic cancer. To develop such therapies, it would be useful to devise targets that are easy to obtain and can indicate the efficacy of these new therapies in models of pancreatic cancer.

31 Jul 2010

Fecal occult blood tests make cost effective alternatives in colorectal cancer screening

While colonoscopies are the most accurate method for the early detection of colorectal cancers, screening with fecal occult blood tests results in more efficient use of limited budgets, according to a new study by researchers at RTI International.

30 Jul 2010

Exact Sciences to demonstrate methylation specific technology at AACC annual meeting

Exact Sciences Corp. today announced that data being presented this afternoon at the annual meeting of the American Association of Clinical Chemistry demonstrates that its methylation specific technology, using a combination of DNA methylation markers, detected 100 percent of colorectal cancers and precancers at a specificity cutoff of 100 percent in a preliminary study with colorectal tissue.

29 Jul 2010

Etubics enters Phase I trials for next generation vector vaccines

Etubics Corporation, a biopharmaceutical company developing next generation vector vaccines, has entered into Phase I trials at Duke University with its ETBX-011, a therapeutic vaccine candidate that is intended to treat Carcinoembryonic Antigen expressing cancers such as colorectal cancer. Etubics dosed its first patient yesterday. Etubics was recently granted clearance by the U.S. Food and Drug Administration for its Investigational New Drug application to begin studying ETBX-011 in humans.

29 Jul 2010

Exact Sciences reports total revenues of $1.3M for second-quarter 2010

Exact Sciences Corp. today announced its financial results for the second quarter ended June 30, 2010.

28 Jul 2010

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.

28 Jul 2010

National health campaigns make men less likely to choose cancer screening: Study

In Germany, several national health campaigns promote cancer screening by announcing that only one in five German men gets screened. This is supposed to motivate men to have an examination. But a new study published in Psychological Science, a journal of the Association for Psychological Science, finds that this well-meaning message has the exact opposite effect: it makes men less likely to choose to get screened.

28 Jul 2010

Axela acquires Xceed Molecular

Axela Inc., an innovator in systems that multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The new Axela will be introduced at the 2010 American Association of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, which takes place July 25 – 29 at the Anaheim Convention Center in California.

26 Jul 2010

Research roundup: Hospital emergency room HIV screenings; Medical device reviews; Health law impact on docs and hospitals

Physician Satisfaction With Chronic Care Processes: A Cluster-Randomized Trial Of Guided Care - The authors randomly assigned teams of physicians and their chronically ill older patients into groups that either provided Guided Care - an educated registered nurse works with a primary care practice team to enhance quality of care - or usual care. One year later, they measured "physicians' satisfaction with chronic care processes, time spent on chronic care, knowledge of their chronically ill older patients, and care coordination provided by physicians and office staff."

26 Jul 2010

Lack of insurance coverage and fees deter willingness to undergo CTC for colorectal cancer screening

A recent questionnaire submitted to a group of patients at one of the nation's largest general hospitals suggests that a significant number of patients, who have previously refused colorectal cancer screening, are willing to undergo computed tomography colonography (CTC) (or virtual colonoscopy), but not willing to pay for the exam themselves when not covered by insurance, according to a study in the August issue of the American Journal of Roentgenology (www.ajronline.org).

22 Jul 2010

Affymetrix second-quarter total revenue decreases to $71.7 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2010. Total revenue for the quarter was $71.7 million, in line with previously announced expectations, as compared to total revenue of $81.6 million in the second quarter of 2009.

22 Jul 2010

Researchers find that increase in leptin may promote colorectal neoplasms

Now, for the first time, a collaborative study of researchers at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University's College of Science and Technology and the Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy have found that an increase in leptin, a cytokine that is normally increased in obese or overweight individuals, may promote colorectal neoplasms by activating colorectal cancer stem cells.

21 Jul 2010

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Curis reports net loss of $2.1 million for second-quarter 2010

New trend in management of post-liver transplantation biliary strictures

NYU PRC receives $3.2M award to establish Comparative Effectiveness Research Program

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Exposure of mBM-MSCs to VPA increases hepatic differentiation

Patients with malignant gastrointestinal disease show high prevalence of malnutrition

Galangin mediates apoptosis of hepatocellular carcinoma cells through mitochondrial pathway: Study

CD74 can serve as prognostic marker for colorectal cancer

Functional MRI can be used to assess tumor viability

Fecal occult blood tests make cost effective alternatives in colorectal cancer screening

Exact Sciences to demonstrate methylation specific technology at AACC annual meeting

Etubics enters Phase I trials for next generation vector vaccines

Exact Sciences reports total revenues of $1.3M for second-quarter 2010

Regeneron second-quarter total revenues increase to $115.9 million

National health campaigns make men less likely to choose cancer screening: Study

Axela acquires Xceed Molecular

Research roundup: Hospital emergency room HIV screenings; Medical device reviews; Health law impact on docs and hospitals

Lack of insurance coverage and fees deter willingness to undergo CTC for colorectal cancer screening

Affymetrix second-quarter total revenue decreases to $71.7 million

Researchers find that increase in leptin may promote colorectal neoplasms

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in